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Effects of Long-Term Use of Nonoxynol-9 on Vaginal Flora
Abstract
OBJECTIVE—Products containing nonoxynol-9 have been used as spermicidal contraceptives for many
years, but limited data have been published describing the long-term effects of nonoxynol-9 use on the vaginal
microbial ecosystem. This longitudinal study was conducted to examine the effects of nonoxynol-9 on the
vaginal ecology.
METHODS—Vaginal swabs were obtained from 235 women enrolled in a randomized clinical trial before
initiation of use of 1 of 5 different formulations of nonoxynol-9 for contraception, and up to 3 more samples
were gathered over 7 months of use. The swab samples were evaluated in a single laboratory. The prevalence of
several constituents of the normal vaginal flora was evaluated. The associations between nonoxynol-9 dosage,
formulation, average product use per week, and number of sex acts per week were calculated.
RESULTS—The changes in prevalence of vaginal microbes after nonoxynol-9 use were minimal for each of
the different nonoxynol-9 formulations. However, when both nonoxynol-9 concentration and number of
product uses are taken into account, nonoxynol-9 did have dose-dependant effects on the increased
prevalence of anaerobic gram-negative rods (odds ratio [OR] 2.4, 95% confidence interval [CI] 1.1–5.3),
H2O2-negative lactobacilli (OR 2.0, 95% CI 1.0–4.1), and bacterial vaginosis (OR 2.3, 95% CI 1.1–4.7).
CONCLUSION—This study demonstrated that most nonoxynol-9 users experienced minimal disruptions in
their vaginal ecology. There were no differences between the different formulations evaluated with respect to
changes in vaginal microflora. However, independent of the nonoxynol-9 formulation, there was a dose-
dependent effect with increased exposure to nonoxynol-9 on the risk of bacterial vaginosis and its associated
flora.
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Abstract
OBJECTIVE—Products containing nonoxynol-9 have been used as spermicidal contraceptives for
many years, but limited data have been published describing the long-term effects of nonoxynol-9
use on the vaginal microbial ecosystem. This longitudinal study was conducted to examine the effects
of nonoxynol-9 on the vaginal ecology.
METHODS—Vaginal swabs were obtained from 235 women enrolled in a randomized clinical trial
before initiation of use of 1 of 5 different formulations of nonoxynol-9 for contraception, and up to
3 more samples were gathered over 7 months of use. The swab samples were evaluated in a single
laboratory. The prevalence of several constituents of the normal vaginal flora was evaluated. The
associations between nonoxynol-9 dosage, formulation, average product use per week, and number
of sex acts per week were calculated.
RESULTS—The changes in prevalence of vaginal microbes after nonoxynol-9 use were minimal
for each of the different nonoxynol-9 formulations. However, when both nonoxynol-9 concentration
and number of product uses are taken into account, nonoxynol-9 did have dose-dependant effects on
the increased prevalence of anaerobic gram-negative rods (odds ratio [OR] 2.4, 95% confidence
interval [CI] 1.1–5.3), H2O2-negative lactobacilli (OR 2.0, 95% CI 1.0–4.1), and bacterial vaginosis
(OR 2.3, 95% CI 1.1–4.7).
CONCLUSION—This study demonstrated that most nonoxynol-9 users experienced minimal
disruptions in their vaginal ecology. There were no differences between the different formulations
evaluated with respect to changes in vaginal microflora. However, independent of the nonoxynol-9
formulation, there was a dose-dependent effect with increased exposure to nonoxynol-9 on the risk
of bacterial vaginosis and its associated flora.
LEVEL OF EVIDENCE—II-2
Products containing nonoxynol-9 have been used as vaginal spermicides for decades and are
a widely used method of family planning. In the past several years, these products have also
been evaluated as topical microbicides for prevention of sexually transmitted infections
including human immunodeficiency virus (HIV).1 Most of these studies were done in sex
workers and did not demonstrate that women who used nonoxynol-9 had a decreased risk of
sexually transmitted infection. Over the past decade, the importance of an intact vaginal
ecosystem in resistance to urogenital infection has been highlighted. Most of the published
data describing the effects of nonoxynol-9 use on the vaginal microbial ecosystem have
assessed short-term nonoxynol-9 exposures, and their effects on the vaginal ecosystem have
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raised some concern. Women with vaginal colonization by lactobacilli are less likely to
have2 and acquire3 sexually transmitted infections such as herpes simplex virus 24 and human
papilloma virus5 and are also less likely to acquire bacterial vaginosis.3 Two cross-sectional
studies and 1 longitudinal study have shown an association between the presence of vaginal
lactobacilli and decreased prevalence or incidence of HIV.6–8 Whether nonoxynol-9 affects
lactobacilli colonization and the integrity of the vaginal ecosystem remains unclear.
Some in vitro studies have suggested that use of spermicides containing nonoxynol-9 would
decrease colonization by lactobacilli,9 whereas others have reported that most peroxide-
producing strains of lactobacilli are resistant to nonoxynol-9.10 The mechanism, however, by
which nonoxynol-9 might alter the vaginal ecology in vivo is not clear, and whether these
vaginal flora alterations are clinically relevant has not been elucidated. There are studies that
have shown an adverse association between nonoxynol-9 use and the maintenance of vaginal
flora,9 although other clinical studies have not confirmed this association.11 Some evidence
suggests that nonoxynol-9 does not increase the risk of either vulvovaginal candidiasis11,12
or bacterial vaginosis,13 and that vaginal epithelia remain intact at lower doses of
nonoxynol-9.12 However, because certain doses of nonoxynol-9 seem to be at least transiently
disruptive to vaginal ecology,14,15 this study was designed to investigate the effect of long-
term use and average weekly dose of 5 different formulations of nonoxynol-9 on vaginal flora
in sexually active women in mutually monogamous relationships.
MATERIALS AND METHODS
This study was conducted at 3 sites between June 1998 and August 2002 as a planned substudy
of a multicenter, randomized trial of the contraceptive effectiveness and safety of nonoxynol-9.
The institutional review boards at each site approved the trial before commencement. All
participants underwent an informed consent process. The details of the multicenter trial design
and primary results have been published.16 Briefly, sexually active women from 18–40 years
of age with no history of subfertility and at low risk for sexually transmitted infections were
eligible. At screening, all women underwent an interview, pelvic examination including Pap
test, wet preparation, and urine pregnancy test. As a part of the larger multicenter trial, each
participant was randomly assigned to use 1 of the following 5 nonoxynol-9 formulations as
her only method of contraception for 7 months: a 52.5-mg gel, a 100-mg gel, a 150-mg gel, a
100-mg film, and a 100-mg suppository. Follow-up visits 2 through 4 were scheduled at weeks
4, 17, and 30. At each scheduled visit, the participant obtained 2 vaginal specimens by twice
inserting the tip of a swab about one-half to 1 inch into her vagina and rotating it for 10 seconds.
The swabs were placed into a specimen transport tube and sent by research personnel to a
central laboratory for analysis.
Upon enrollment, the site study personnel telephoned a central randomization center to obtain
an assignment to 1 of the 5 nonoxynol-9 formulations. The randomization scheme was
computer-generated at Family Health International before the start of enrollment and was
stratified by site with randomly ordered block sizes. Treatment assignment was not concealed
from the participants or the clinical examiners. However, laboratory personnel were masked
to the treatment assignment.
One swab was rolled across a glass slide and air dried for preparation of a Gram stain for
assessment of vaginal flora. The slides were interpreted by a standard method for the diagnosis
of bacterial vaginosis described by Nugent et al.17 A score of 0 to 3 was interpreted as
consistent with normal, Lactobacillus-predominant flora, a score of 4 to 6 corresponded to
intermediate flora, and a score of 7–10 indicated bacterial vaginosis. The other swab was placed
in Amies transport media and transported to the laboratory for culture of Escherichia coli,
Lactobacillus, Candida, Enterococcus, and Staphylococcus. In addition to a 5% sheep blood
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agar plate, a Rogosa agar plate was inoculated for recovery of lactobacilli and incubated in an
anaerobic chamber. Lactobacilli were identified to the genus level by Gram stain morphology
and production of lactic acid as assessed by gas chromatography. All lactobacilli were tested
for the production of hydrogen peroxide in a qualitative assay using tetramethylbenzidine agar.
Anaerobic gram-negative rods were detected on Brucella agar after 4–5 days of incubation
under anaerobic conditions.
The sample size was estimated based on previous studies evaluating the effect of the diaphragm
plus Conceptrol gel (Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) on vaginal microflora,
which demonstrated an increase in the prevalence of E. coli from 15% before spermicide use
to 48% after spermicide use.18 Based on a 2-tailed McNemar’s χ2 test at the 0.05 significance
level, a sample size of 40 women in each group, or a total of 200 women, would have 80%
power to demonstrate similar increases in the prevalence of E. coli and other organisms between
baseline and follow-up. The sample size was increased to a convenient number of 255 women,
which allowed for a 22% discontinuation rate. A sample size of 47 in each group would have
80% power to detect a minimal between-group difference of 22% in the prevalence of E.
coli after spermicide use.
All statistical analyses were performed using Stata statistical software, release 8.0 (StataCorp,
College Station, TX), and all statistical tests were evaluated at the .05 significance level.
Differences in the baseline characteristics of the women randomly assigned to the 5
nonoxynol-9 formulation groups were evaluated using analysis of variance or Pearson’s χ2, as
appropriate. Vaginal colonization by hydrogen peroxide-producing and hydrogen peroxide-
negative Lactobacillus, Gardnerella vaginalis, E. coli, Enterococcus, anaerobic gram-negative
rods, and yeast was defined as detection of growth of the organism from agar culture.
Differences in the prevalence of vaginal microbes and a Gram stain diagnosis of bacterial
vaginosis at each visit among the nonoxynol-9 formulation groups were evaluated using
Pearson’s χ2. Paired differences in prevalence between visits within an nonoxynol-9
formulation group were evaluated using McNemar’s χ2 test.
Average weekly nonoxynol-9 dose was calculated by multiplying the number of times the
participant used the product, as obtained from the subjects’ coital diaries, by the dose of
nonoxynol-9 in that product and then dividing by the number of weeks since the prior visit.
Generalized estimating equations were used to identify factors that were associated with the
prevalence of vaginal microbial colonization and Gram stain diagnosis of bacterial vaginosis
after spermicide use. Generalized estimating equations were also used to identify organisms
associated with the prevalence of self-reported symptoms after spermicide use. Generalized
estimating equations are a regression method that is able to model the marginal expectation of
repeated, correlated outcomes. An exchangeable working correlation matrix was specified that
assumes a common within-group correlation, and modified sandwich estimates of the variance
were calculated, which produces valid standard errors even if the within-group correlation
structure is not correctly specified. Sandwich estimates of the variance combine the variance
estimate for the specified model with the variance matrix constructed from the data. The
sandwich estimate is then modified to consider the sums of the observations for each individual.
Statistical inference was based on the generalized Wald test statistic.19 Multivariate
generalized estimating equations models were developed using forward stepwise regression.
Variables were retained in the model if the Wald test statistic had a P value of 0.05 or less.
Models for the prevalence of each organism after spermicide use were adjusted for baseline
colonization status. The population averaged odds ratios derived from the generalized
estimating equations models are presented along with the 95% confidence intervals and P
values.
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RESULTS
A total of 269 women were enrolled and 235 (87%) completed between 2 and 4 visits. The
median time between the enrollment visit and visits 2, 3, and 4 were 4, 17, and 30 weeks,
respectively. Of the 235 women with follow-up, 46 (20%) were assigned to use the 52.5-mg
gel, 43 (18%) the 100-mg gel, 46 (20%) the 150-mg gel, 51 (22%) the 100-mg film, and 49
(21%) the 100-mg suppository. Sixty-four percent of the participants used their assigned
spermicide with every coital act. The demographic characteristics of the 235 participants with
follow-up are displayed in Table 1. The most common contraceptive method used by the
women in all groups was the oral contraceptive pill (used by 75% of study participants at some
point in the past). However, a range of contraceptive methods were used by these women,
including implants, depomedroxyprogesterone acetate, condoms (male and female),
intrauterine devices, spermicides, diaphragm, periodic abstinence, and withdrawal. There was
no statistically significant difference in the types of contraceptives used across the 5 groups.
Reports of urogenital symptoms and infections were not statistically significantly different
among the groups, and few (1–3%) had symptoms within the week before enrollment.
The proportion of women with colonization by the individual microorganisms at baseline and
subsequent visits are listed in Table 2. There was an overall difference at visit 2 in the
percentage of women with an increase the prevalence of yeast, and there was a difference in
the presence of H2O2-negative lactobacilli at visit 3 as well with Enterococcus at visit 4. In the
52.5-mg gel group, there was a statistically significant increase in Enterococcus from the
baseline visit to visit 2, but this resolved by visit 3. In the 100-mg film group, the number of
H2O2-negative lactobacilli decreased significantly between visits 2 and 3, and this effect was
persistent.
Symptomatology was uncommon in this study. Thirty women were colonized with Candida
spp after nonoxynol-9 use, and a statistically significant proportion of these women complained
of vaginal burning (P = .002), vaginal itching (P = .004), and vulvar burning (P = .04). Pelvic
pain and vaginal bleeding were not associated with vaginal flora disturbances, but dyspareunia
was associated with the presence of Gardnerella vaginalis (P = .03). There were no significant
complaints that were associated with a diagnosis of bacterial vaginosis.
There was a decrease in the prevalence of yeast in those women who used the film and
suppository nonoxynol-9 formulation, even after controlling for baseline colonization status.
The prevalence of anaerobic gram-negative rods was increased in those who used the 100-mg
gel, but the prevalence of Enterococcus was decreased in this same group.
Colonization at baseline was the most significant risk factor for colonization with the same
microbe later at follow-up (P < .001 for each). African-American women had a statistically
significantly increased risk for Gardnerella vaginalis colonization (odds ratio [OR] 2.7, 95%
confidence interval [CI] 1.6–4.5), anaerobic gram-negative colonization (OR 2.5, 95% CI 1.2–
4.9), and bacterial vaginosis (OR 3.6, 95% CI 1.9–6.7) when compared with women of other
races. African-American race was also associated with a decreased risk of colonization by
H2O2-producing lactobacilli (OR 0.5, 95% CI 0.3–0.8). Vaginal micro-flora did differ between
sites, but these differences were attributable to differences in ethnic distribution by site. Thus,
after statistical adjustment for race, site-specific differences in vaginal microflora were no
longer significant. Similarly, the type of nonoxynol-9 delivery system had limited impact on
microbe colonization (Table 3) after accounting for baseline microbe colonization.
To test the hypothesis that increased weekly exposure to nonoxynol-9 accounted for changes
in the vagina microflora, average weekly nonoxynol-9 exposures were categorized based on
quartiles as< 100 mg, 100–174 mg, 175–281 mg, and > 281 mg. There was a dose-dependant
relationship between average weekly nonoxynol-9 exposure and an increase in the prevalence
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of anaerobic gram-negative rods and bacterial vaginosis, even after adjustment for baseline
colonization (Table 4). The increased risk for bacterial vaginosis and anaerobic gram-negative
rods associated with nonoxynol-9 exposure was present even after adjustment for race (OR
2.2, 95% CI 1.1–4.4; OR 2.4, 95% CI 1.1–5.3, respectively).
The mean number of coital acts, product usages, and average milligram dose of nonoxynol-9
per week are shown in Table 5. With the exception of those participants in the 100-mg gel
group, there was no difference in number of coital acts per week among the groups. This group
also accounts for the difference found in product use per week. Average milligram dose per
week was predictably increased with the higher-dose nonoxynol-9 formulations and also
increased in the group who used the 100-mg nonoxynol-9 gel (because that group had more
coital acts per week).
DISCUSSION
This longitudinal investigation did not show dramatic effects of nonoxynol-9 on the vaginal
ecologic system. The most significant risk factor for being colonized with an organism after
spermicide use was baseline colonization, not nonoxynol-9 exposure. However, even after
adjustment for colonization status at baseline and for race, an increase in nonoxynol-9 exposure
was associated with a statistically significant increase in colonization by anaerobic gram-
negative rods, H2O2-negative lactobacilli, and bacterial vaginosis. Furthermore, the vehicle
itself, gel, film, and suppository, was not generally associated with changes in the vaginal
ecology independent of nonoxynol-9 dose. Rather, it was the average nonoxynol-9 exposure
per week, which reflects the number of sex acts with spermicide, as well as the dose of each
application used that increased the risk for vaginal flora disturbances.
The clinical significance of this dose-dependant relationship is less clear than its statistical
significance; symptomatology was uncommon in this trial. The laboratory diagnosis of
bacterial vaginosis, as opposed to the clinical diagnosis, was used in this study because this
testing can be standardized across sites. Not all of the women with a Gram stain consistent
with bacterial vaginosis would have fulfilled the clinical criteria for the diagnosis of bacterial
vaginosis. Nevertheless, an increase in the dose of nonoxynol-9 was associated with vaginal
ecologic disruptions, and whether these changes predispose women to HIV or other virulent
sexually transmitted infections remains an important question. Even if the dose-dependant
changes in the vaginal flora did not produce symptoms in the study population, it is possible
that the changes themselves create an environment that facilitates infection with sexually
transmitted infections. Nonoxynol-9 use would clearly be limited if this were the case.
The population studied here is representative of people who are in long-standing, mutually
monogamous relationships. In this sample, nonoxynol-9 was not generally disruptive to the
vaginal flora. Because of the low incidence of sexually transmitted infections in the study
population, associations between nonoxynol-9, vaginal ecologic disruption, and sexually
transmitted infection transmissibility could not be delineated. However, studies have
demonstrated an association of nonoxynol-9 use with increased HIV acquisition in the sex
worker population,20,21 where increased weekly dose may have been a factor. An association
with the presence of bacterial vaginosis and increased HIV prevalence has been described.6 It
is possible that the increase in bacterial vaginosis that is found with increased nonoxynol-9
dose in this study is an intermediate state for the increased HIV incidence that has been found
on other studies. Further research in this area is necessary to test this hypothesis.
Eighty-seven percent of the participants completed 75% of the planned follow-up visits.
Weaknesses of the study include that the both product use and frequency of coital acts were
dependant upon information extracted from participant diaries. There was no objective way to
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verify this information. Another weakness of the analysis is the lack of control group for
comparison.
Overall, this trial supports the safety of nonoxynol-9 as a contraceptive with respect to its effects
on the vaginal ecosystem. Raymond et al16 recently showed that these 5 nonoxynol-9
formulations are safe and effective forms of contraception, with increased dose being
associated with increased efficacy. Although we found that there was clearly an effect of
increased dose of nonoxynol-9 on the vaginal ecosystem, this effect was present only among
the most frequent users.
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Table 3
Odds Ratios of Microbe Colonization by Nonoxynol-9 Delivery System, Adjusted for Baseline Colonization
Microbe/Nonoxynol-9 Formulation Odds Ratio (95% Confidence Interval)
H2O2+ Lactobacilli
 52.5-mg gel 1.0 (referent)
 100-mg gel 0.8 (0.3–2.0)
 150-mg gel 0.7 (0.4–1.4)
 100-mg film 0.5 (0.2–1.1)
 100-mg suppository 0.7 (0.3–1.5)
H2O2– Lactobacilli
 52.5-mg gel 1.0 (referent)
 100-mg gel 0.9 (0.4–1.9)
 150-mg gel 1.2 (0.5–2.9)
 100-mg film 0.8 (0.4–1.7)
 100-mg suppository 1.3 (0.6–2.9)
Gardnerella vaginalis
 52.5-mg gel 1.0 (referent)
 100-mg gel 1.1 (0.5–2.6)
 150-mg gel 0.8 (0.4–1.9)
 100-mg film 1.4 (0.7–3.0)
 100-mg suppository 1.0 (0.4–2.2)
Escherichia coli
 52.5-mg gel 1.0 (referent)
 100-mg gel 0.7 (0.4–1.3)
 150-mg gel 1.0 (0.6–1.8)
 100-mg film 0.7 (0.4–1.4)
 100-mg suppository 1.4 (0.8–2.6)
Enterococcus
 52.5-mg gel 1.0 (referent)
 100-mg gel 0.5 (0.2–0.9)
 150-mg gel 0.6 (0.3–1.2)
 100-mg film 0.5 (0.3–1.0)
 100-mg suppository 0.9 (0.4–1.9)
Anaerobic gram-negative rods
 52.5-mg gel 1.0 (referent)
 100-mg gel 3.6 (1.3–10.4)
 150-mg gel 1.7 (0.7–4.0)
 100-mg film 1.0 (0.5–2.3)
 100-mg suppository 2.3(0.9–5.6)
Bacterial Vaginosis gram stain
 52.5-mg gel 1.0 (referent)
 100-mg gel 2.0 (0.8–5.4)
 150-mg gel 1.2 (0.5–2.4)
 100-mg film 1.4 (0.6–3.5)
 100-mg suppository 0.7 (0.4–1.4)
Yeast
 52.5-mg gel 1.0 (referent)
 100-mg gel 0.9 (0.4–2.4)
 150-mg gel 0.4 (0.1–1.1)
 100-mg film 0.1 (0.02–0.5)
 100-mg suppository 0.4 (0.1–0.96)
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Table 4
Odds Ratios of Microbe Colonization by Nonoxynol-9 Dose, Adjusted for Baseline Colonization
Microbe/Average Nonoxynol-9 Dose per Wk Odds Ratio (95% Confidence Interval) P
H2O2+ Lactobacilli
 < 100 mg 1.0 (referent)
 100–174 mg 1.2 (0.7–2.1) .6
 175–281 mg 0.9 (0.5–1.7) .8
 > 281 mg 0.7 (0.4–1.4) .3
H2O2– Lactobacilli
 < 100 mg 1.0 (referent)
 100–174 mg 1.2 (0.7–2.2) .7
 175–281 mg 0.9 (0.4–1.8) .7
 > 281 mg 2.0 (1.0–4.1) .04
Gardnerella vaginalis
 < 100 mg 1.0 (referent)
 100–174 mg 1.8 (1.0–3.2) .06
 175–281 mg 1.6 (0.9–2.8) .1
 > 281 mg 1.8 (0.9–3.4) .08
Escherichia coli
 < 100 mg 1.0 (referent)
 100–174 mg 1.0 (0.6–1.7) .9
 175–281 mg 0.9 (0.5–1.5) .7
 > 281 mg 1.3 (0.8–2.1) .4
Enterococcus
 < 100 mg 1.0 (referent)
 100–174 mg 1.3 (0.7–2.2) .4
 175–281 mg 0.9 (0.5–1.5) .6
 > 281 mg 1.1 (0.6–2.1) .7
Anaerobic gram-negative rods
 < 100 mg 1.0 (referent)
 100–174 mg 1.2 (0.6–2.2) .6
 175–281 mg 1.4 (0.7–2.6) .3
 > 281 mg 2.4 (1.1–5.3) .02
Bacterial vaginosis gram stain
 < 100 mg 1.0 (referent)
 100–174 mg 1.7 (0.9–3.3) .1
 175–281 mg 1.6 (0.8–3.2) .2
 > 281 mg 2.3 (1.1–4.7) .02
Yeast
 < 100 mg 1.0 (referent)
 100–174 mg 1.7 (0.9–3.3) .1
 175–281 mg 1.6 (0.8–3.2) .2
 > 281 mg 2.3 (1.1–4.7) .02
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